STOCK TITAN

AgomAb Therapeutics NV (AGMB) SEC Filings

AGMB NASDAQ

Agomab Therapeutics NV filings document the company's foreign private issuer reports, ADS public offering disclosures, governance materials, and clinical-stage biopharmaceutical updates. Form 6-K reports have included the closing of the company's initial public offering of American Depositary Shares, amended and restated articles of association, press releases, annual meeting materials, proxy forms, and voting documentation.

AGMB's regulatory record also discloses capital-structure matters tied to ADSs and common shares, incorporation of materials into a Form S-8 registration statement, financial results, business updates, shareholder voting matters, and clinical or regulatory disclosures related to its fibro-inflammatory disease programs.

Rhea-AI Summary

For AgomAb Therapeutics NV (AGMB), Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report beneficial ownership of 1,740,230 common shares, or 3.5%, as of September 30, 2026. The reports concern the same position, not three separate holdings: the American Depositary Shares are directly held by Redmile Biopharma Investments III, and each ADS represents one common share.

Redmile and Green may be deemed beneficial owners through Redmile’s role as investment manager and Green’s role as its principal; each disclaims beneficial ownership except to the extent of any pecuniary interest. The 3.5% calculation uses 49,247,975 common shares outstanding as of March 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) director David R. Epstein purchased 14,980 common shares directly on November 13, 2026, across four reported transactions: 5,000 at $5.99, 20 at $6.00, 5,000 at $5.75 and 4,960 at $6.02 per share. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) director David R. Epstein bought 15,000 common shares on November 5, 2026, across three reported purchases of 5,000 shares each. The reported prices were $6.81, $6.91 and $6.98 per share. The purchases were direct, and no Rule 10b5-1 plan is reported. Common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.54%
Tags
insider
Rhea-AI Summary

AgomAb Therapeutics NV director David R. Epstein reported two direct purchases of 5,000 common shares each on October 21, 2026: 5,000 at $8.86 per share and 5,000 at $8.90 per share, totaling 10,000 shares. The footnote says the common shares may be represented by American Depositary Shares, each currently representing one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
insider
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) announced that the first patient has been dosed in NOV-ERA, its global Phase 2b study of ontunisertib for symptomatic fibrostenosing Crohn’s disease (FSCD). The randomized, double-blind, placebo-controlled study is expected to enroll approximately 320 adult patients. Participants receive ontunisertib at 400 mg, 200 mg or 100 mg twice daily, or matching placebo, for a 52-week treatment period. The primary endpoint is the proportion achieving endoscopic passability of the ileal index stricture at Week 24.

Study initiation triggers a €7 million milestone payment to former Origo Biopharma shareholders under AgomAb’s 2021 acquisition of the company. That acquisition included up to €20 million in potential development and regulatory milestone payments; €10 million has become payable to date, including a €3 million milestone paid in 2025. Ontunisertib is investigational and not approved by any regulatory authority; its efficacy and safety have not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
current report
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) director David R. Epstein purchased 5,000 common shares at $8.90 per share on October 8, 2026. His reported direct holdings after the purchase were 15,000 shares. No Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each currently representing one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
insider
Rhea-AI Summary

AgomAb Therapeutics NV director David R. Epstein bought 5,000 common shares on October 5, 2026, at $8.57 per share, and 5,000 common shares on October 6, 2026, at $8.70 per share. Both purchases were reported as direct transactions, and no Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
insider
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) Chief Financial Officer Pierre Thadee Victor Kemula purchased 10,000 common shares directly on October 6, 2026, across three reported transactions: 3,000 at $8.67 per share, 5,000 at $8.57, and 2,000 at $8.54. No Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each currently representing one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
insider
-
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) Chief Executive Officer and director Tim Jasper Knotnerus reported two direct purchases of common shares: 6,000 at $8.48 on October 5, 2026, and 5,000 at $8.70 on October 6, 2026. No Rule 10b5-1 plan is reported for the purchases.

The report also lists 34,394 common shares held by TJK Life Sciences B.V. Knotnerus exercises voting and dispositive power over those shares and disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest. Each American Depositary Share currently represents one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
insider
Rhea-AI Summary

AgomAb Therapeutics NV (AGMB) reported topline results from the 48-week open-label extension (OLE) of its Phase 2a STENOVA study of ontunisertib in fibrostenosing Crohn’s disease. 49 participants entered the OLE, representing 94% of eligible Part A participants, and 37 completed it. Participants received ontunisertib 200 mg twice daily for up to 48 additional weeks, with treatment reported for up to 60 weeks overall.

The company reported one FSCD-related endoscopic balloon dilation, a 3% annualized event rate, and no surgeries. At Week 48, 97% of evaluable patients were in clinical remission by CDAI. Five serious adverse events occurred in four patients and were considered unrelated or unlikely related to treatment. Imaging assessments suggested stabilization of fibrotic strictures; the company said optional Week 48 endoscopy data were too limited for reliable interpretation. AgomAb plans to initiate the global NOV-ERA Phase 2b study in the coming months, testing three doses or placebo. Ontunisertib is investigational and not approved; its efficacy and safety have not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.07%
Tags
current report

FAQ

How many AgomAb Therapeutics NV (AGMB) SEC filings are available on StockTitan?

StockTitan tracks 42 SEC filings for AgomAb Therapeutics NV (AGMB), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for AgomAb Therapeutics NV (AGMB)?

The most recent SEC filing for AgomAb Therapeutics NV (AGMB) was filed on November 16, 2026.